WO2016027285A3 - Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors - Google Patents

Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors Download PDF

Info

Publication number
WO2016027285A3
WO2016027285A3 PCT/IN2015/050097 IN2015050097W WO2016027285A3 WO 2016027285 A3 WO2016027285 A3 WO 2016027285A3 IN 2015050097 W IN2015050097 W IN 2015050097W WO 2016027285 A3 WO2016027285 A3 WO 2016027285A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
bicyclic heteroaryl
protease inhibitors
treatment
cysteine protease
Prior art date
Application number
PCT/IN2015/050097
Other languages
French (fr)
Other versions
WO2016027285A2 (en
Inventor
Harish Kumar Mysore Nagaraj
Balachandra S BANDODKAR
Lokesh RAVILLA
Sudhakar YELLAPU
Ashok Seegebagi RUDRESHA
Jitendra Kumar Singh
Vaidyanathan. G
Original Assignee
Alkem Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd. filed Critical Alkem Laboratories Ltd.
Publication of WO2016027285A2 publication Critical patent/WO2016027285A2/en
Publication of WO2016027285A3 publication Critical patent/WO2016027285A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to substituted bicyclic heteroaryl amide derivatives that are inhibitors of cathepsin K proteases and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of these enzymes. In addition, the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of bone diseases such as osteoporosis and osteoarthritis as well as other diseases and conditions. The compounds have the general formula: [Formula should be inserted here]
PCT/IN2015/050097 2014-08-22 2015-08-21 Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors WO2016027285A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2703/MUM/2014 2014-08-22
IN2703MU2014 2014-08-22

Publications (2)

Publication Number Publication Date
WO2016027285A2 WO2016027285A2 (en) 2016-02-25
WO2016027285A3 true WO2016027285A3 (en) 2016-04-14

Family

ID=55351354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/050097 WO2016027285A2 (en) 2014-08-22 2015-08-21 Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors

Country Status (1)

Country Link
WO (1) WO2016027285A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018454987A1 (en) * 2018-12-24 2021-07-15 InventisBio Co., Ltd. Novel salts of selective estrogen receptor degraders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019161A1 (en) * 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
WO2006076796A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and obesity
WO2009001129A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019161A1 (en) * 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
WO2006076796A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and obesity
WO2009001129A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIETER BRÖMME ET AL.: "Cathepsin K inhibitors for osteoporosis and potential off-target effects", EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. Isuue 5, May 2009 (2009-05-01), pages 585 - 600 *

Also Published As

Publication number Publication date
WO2016027285A2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
WO2015101957A3 (en) Inhibitors of glutaminase
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2018134685A3 (en) Compounds
WO2016172134A3 (en) Novel compounds
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2018010374A (en) Inhibitors of wdr5 protein-protein binding.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
CR20200362A (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS (Divisional 2016-0395)
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
GEP20156239B (en) Benzofuranyl derivatives used as glucokinase inhibitors
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
TN2017000213A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
WO2016102672A3 (en) Inhibitors of akt kinase
EA201792341A1 (en) DERIVATIVES OF PYRAZOLA SUITABLE AS INHIBITOR PROTEINS ACTIVATING 5-LIPOXYGENASE (FLAP)
SA519401322B1 (en) Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2
WO2016199076A3 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
WO2015195950A8 (en) Lmp7 inhibitors
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2016027284A3 (en) Piperidine ureas as cathepsin cysteine protease inhibitors
WO2015055898A3 (en) Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15833343

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 02.05.2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15833343

Country of ref document: EP

Kind code of ref document: A2